Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


Ultra-broadband, polarization-independent, wide-angle absorption in impedance-matched metamaterials with anti-reflective moth-eye surfaces.

Contractor R, D'Aguanno G, Menyuk C.

Opt Express. 2018 Sep 3;26(18):24031-24043. doi: 10.1364/OE.26.024031.


Comparative evaluation of thoracoscopy versus thoracotomy in the management of lung hydatid disease.

Mehta KD, Gundappa R, Contractor R, Sangani V, Pathak A, Chawda P.

World J Surg. 2010 Aug;34(8):1828-31. doi: 10.1007/s00268-010-0581-6.


Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.

Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL.

Cancer Res. 2008 Jul 15;68(14):5743-52. doi: 10.1158/0008-5472.CAN-08-0235.


Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M.

Cancer Res. 2008 May 1;68(9):3413-20. doi: 10.1158/0008-5472.CAN-07-1919.


The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.

Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS.

Clin Cancer Res. 2008 Jan 1;14(1):230-9. doi: 10.1158/1078-0432.CCR-07-1440.


PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.

Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M.

Cancer Biol Ther. 2007 Dec;6(12):1967-77. Epub 2007 Sep 4.


Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.

Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S, Xu Y, Tsutusmi-Ishii Y, Miyake K, Miyake N, Kondo S, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M.

Cell Death Differ. 2007 Aug;14(8):1443-56. Epub 2007 Apr 27.


Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.

Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M.

Br J Cancer. 2007 Feb 12;96(3):445-9. Epub 2007 Jan 23.


An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M.

Cancer Res. 2007 Jan 1;67(1):209-17.


Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, Tuveson DA, Huang PS.

Cancer Res. 2006 Dec 1;66(23):11100-5.


Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M.

Cancer Cell. 2006 Nov;10(5):375-88.


PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.

Tabe Y, Konopleva M, Kondo Y, Contractor R, Jin L, Ruvolo V, Tsutsumi-Ishii Y, Miyake K, Miyake N, Ohsaka A, Nagaoka I, Issa JP, Andreeff M.

Ann Hematol. 2006 Oct;85(10):689-704. Epub 2006 Jul 11.


Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML.

Kurinna S, Konopleva M, Palla SL, Chen W, Kornblau S, Contractor R, Deng X, May WS, Andreeff M, Ruvolo PP.

Leukemia. 2006 Jul;20(7):1316-9. Epub 2006 Apr 27. No abstract available.


A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate: direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis.

Samudio I, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann W, Ying Y, Evans R, Contractor R, Andreeff M.

Mol Pharmacol. 2006 Apr;69(4):1182-93. Epub 2006 Jan 12.


Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.

Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA, Andreeff M.

Cancer Res. 2005 Nov 1;65(21):9962-70.


Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.

Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J, Andreeff M.

Blood. 2006 Feb 15;107(4):1546-54. Epub 2005 Oct 13.


The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.

Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M, Ruvolo PP.

Leukemia. 2005 Aug;19(8):1350-4.


Targeted therapy of AML new concepts.

Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M.

Ann Hematol. 2004;83 Suppl 1:S51-3. No abstract available.


HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India.

Saranath D, Khan Z, Tandle AT, Dedhia P, Sharma B, Contractor R, Shrivastava S, Dinshaw K.

Gynecol Oncol. 2002 Aug;86(2):157-62.


Supplemental Content

Loading ...
Support Center